Improvement of Planning Skills in Children and Adolescents With ADHD Through a Virtual Reality System: CogFun-RV
NCT05368324, Not applicable, Unknown, Universidad de Granada
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Improvement of Planning Skills in Children and Adolescents With ADHD Through a Virtual Reality System: CogFun-RV | ClinicalTrials.gov |
| NCT number | NCT05368324 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 82 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universidad de Granada | ClinicalTrials.gov |
| Conditions | ADHD | ClinicalTrials.gov |
| Interventions | CogFun-RV | ClinicalTrials.gov |
| First posted | 2022-05-10 | ClinicalTrials.gov |
| Last updated | 2022-05-20 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD | After the Intervention (12 weeks) | The Weiss Functional Impairment Rating Scale- Parent Form (WFIRS-P) is a 50-item scale that assesses functional impairment on six clinically relevant domains typically affected in attention-deficit/hyperactivity disorder (ADHD) | ClinicalTrials.gov |
| Primary | Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD | At 3 months | The Weiss Functional Impairment Rating Scale Parent Form (WFIRS-P) is a 50-item scale that assesses functional impairment on six clinically relevant domains typically affected in attention-deficit/hyperactivity disorder (ADHD) | ClinicalTrials.gov |
| Primary | Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD | At 6 months | The Weiss Functional Impairment Rating Scale- Parent Form (WFIRS-P) is a 50-item scale that assesses functional impairment on six clinically relevant domains typically affected in attention-deficit/hyperactivity disorder (ADHD) | ClinicalTrials.gov |
| Primary | Self-assessment of daily time management in children (TIME-S) | After the intervention: 12 weeks | Self-assessment for children with disabilities ages 10-17 ability of time perception, time orientation andknowledge on time management in children 10-17 years old | ClinicalTrials.gov |
| Primary | Self-assessment of daily time management in children (TIME-S) | At 3 months | Self-assessment for children with disabilities ages 10-17 ability of time perception, time orientation andknowledge on time management in children 10-17 years old | ClinicalTrials.gov |
| Primary | Self-assessment of daily time management in children (TIME-S) | At 6 months | Self-assessment for children with disabilities ages 10-17 ability of time perception, time orientation andknowledge on time management in children 10-17 years old | ClinicalTrials.gov |
| Secondary | Assessment of Executive Function and Sensory Processing (EPYFEI) | Before and after the intervention (12 weeks) | Questionnaire for parent.Scores above 46.5 points indicate that there is a deficit in executive functioning in daily life. The higher the score, the worse the result. | ClinicalTrials.gov |
| Secondary | Conners Behavior Questionnaire for Parents (SNAP-IV) | Before and after the intervention (12 weeks) | Behavior scale for children and adolescents with ADHD. Higher score mean worse outcome. | ClinicalTrials.gov |
| Secondary | Zoo Map Subtest | Before and after the intervention (12 weeks) | Planning Skills Cognitive Test.The number of errors is scored, the higher the score, the worse the results. The scores are between 0 and 10. | ClinicalTrials.gov |
| Secondary | Stroop Test | Before and after the intervention (12 weeks) | Cognitive test of selective attention and interference inhibition.The score can be positive or negative. If the score is negative, below zero, it indicates that there are difficulties in inhibiting interference from the environment. | ClinicalTrials.gov |
| Secondary | Trail Making Test | Before and after the intervention (12 weeks) | Cognitive test of sustained and alternating attention.The number of errors and the time it takes to complete the task are collected. Scores vary by age. The higher the number of errors and the longer the execution time, the worse the attention. | ClinicalTrials.gov |
| Secondary | Digit test | Before and after the intervention (12 weeks) | Attentional Span and Working Memory.The higher the score, the better the results. Normal scores range between 6 and 9 digits of attention span. | ClinicalTrials.gov |
| Secondary | Emotional intelligence scale EQ-i:Yv | Before and after the intervention (12 weeks) | Emotional intelligence scale for children and young people.The higher the score, the better the results. The average scores are between 90-100 points. | ClinicalTrials.gov |
| Secondary | Strengths and Difficulties Questionnaire (SDQ)-parents | Before and after the intervention (12 weeks) | Assessment of behavioural problems.The minimum score is 0 and the maximum is 40. The normal score is between 0-13 points. A score greater than 17 was considered abnormal. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)